Prelude Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-1,495
| Closed | -$5K | – | 2387 |
|
|
2018
Q3 | $5K | Buy |
1,495
+1,489
| +24,817% | +$5.37K | ﹤0.01% | 1641 |
|
|
2018
Q2 | $0 | Sell |
6
-1,411
| -100% | -$6.87K | ﹤0.01% | 2108 |
|
|
2018
Q1 | $6K | Buy |
1,417
+236
| +20% | +$1.1K | ﹤0.01% | 1412 |
|
|
2017
Q4 | $5K | Sell |
1,181
-10
| -0.8% | -$55 | ﹤0.01% | 1273 |
|
|
2017
Q3 | $8K | Sell |
1,191
-307
| -20% | -$2.21K | ﹤0.01% | 1468 |
|
|
2017
Q2 | $11K | Sell |
1,498
-20,011
| -93% | -$125K | ﹤0.01% | 1389 |
|
|
2017
Q1 | $132K | Buy |
+21,509
| New | +$118K | 0.01% | 697 |
|
|
2014
Q4 | – | Sell |
-5,000
| Closed | -$77.5K | – | 2294 |
|
|
2014
Q3 | $69K | Sell |
5,000
-200
| -4% | -$3.06K | 0.01% | 1267 |
|
|
2014
Q2 | $80K | Buy |
5,200
+3,800
| +271% | +$53.9K | 0.01% | 1193 |
|
|
2014
Q1 | $24K | Sell |
1,400
-126,100
| -99% | -$1.9M | ﹤0.01% | 1637 |
|
|
2013
Q4 | $1.65M | Buy |
127,500
+2,500
| +2% | +$29.9K | 0.27% | 66 |
|
|
2013
Q3 | $1.26M | Hold |
125,000
| – | – | 0.2% | 91 |
|
|
2013
Q2 | $934K | Buy |
+125,000
| New | +$977K | 0.2% | 114 |
|
Prelude Capital Management's KERX Position: Q4 2018 in Review
Prelude Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 1,495 shares — an estimated $5K sold.
Prelude Capital Management first reported a position in KERX in Q2 2013 and held it in 13 quarters. The position peaked at $1.65M in Q4 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Prelude Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Prelude Capital Management sold 1,495 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $5K.
- Prelude Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
- Prelude Capital Management's Keryx Biopharmaceuticals Inc position peaked at $1.65M in Q4 2013.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.